Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
J Surg Oncol. 2012 Nov;106(6):667-73. doi: 10.1002/jso.23198. Epub 2012 Jun 11.
To determine whether the patterns of failure are correlated with the degree of response to preoperative chemoradiotherapy (CRT) and to evaluate outcomes after recurrence in rectal cancer patients who underwent CRT followed by resection.
Response to CRT was evaluated according to tumor regression grade (TRG), with 581 patients categorized into two groups, a good response (GR, TRG 3/4, n = 224) and a poor response (PR, TRG 1/2, n = 357) group.
At a mean follow-up of 61 months, the 5-year overall (88.2% vs. 71.3%, P < 0.001) and disease-free (86.7% vs. 63.6%, P < 0.001) survival rates were higher in the GR group. In patients with recurrence, time to recurrence was shorter (13.5 months vs. 18.7 months, P = 0.01), and the cumulative 2-year recurrence rates (92.9% vs. 73.4%, P = 0.024) was higher in the GR group. Rates of local (1.3% vs. 9.5% P < 0.001) and systemic (11.6% vs. 27.2%, P < 0.001) recurrence were significantly lower in the GR group, as were rates of pulmonary (3.6% vs. 15.1%, P < 0.001) and systemic lymph node (1.3% vs. 5.9%, P = 0.009) recurrences. The 5-year overall survival rates after recurrence were similar (GR: 23.7% vs. PR: 16.0%, P = 0.911).
More than one-third of patients with locally advanced rectal cancer showed good response to CRT, with improved local and systemic recurrence rates, especially low rates of pulmonary and systemic lymph node recurrence. Recurrence occurred earlier in the GR than the PR group, and oncologic outcomes after recurrence did not differ between the two groups.
确定失败模式是否与术前放化疗(CRT)的反应程度相关,并评估接受 CRT 后行切除术的直肠癌患者复发后的结局。
根据肿瘤消退分级(TRG)评估 CRT 反应,581 例患者分为两组,即良好反应(GR,TRG 3/4,n=224)和不良反应(PR,TRG 1/2,n=357)组。
在平均随访 61 个月时,GR 组的 5 年总生存率(88.2%比 71.3%,P<0.001)和无病生存率(86.7%比 63.6%,P<0.001)更高。在复发患者中,GR 组的复发时间更短(13.5 个月比 18.7 个月,P=0.01),2 年累积复发率更高(92.9%比 73.4%,P=0.024)。GR 组局部(1.3%比 9.5%,P<0.001)和全身(11.6%比 27.2%,P<0.001)复发率较低,肺部(3.6%比 15.1%,P<0.001)和全身淋巴结(1.3%比 5.9%,P=0.009)复发率也较低。复发后 5 年总生存率相似(GR:23.7%比 PR:16.0%,P=0.911)。
超过三分之一的局部进展期直肠癌患者对 CRT 有良好反应,局部和全身复发率降低,特别是肺部和全身淋巴结复发率低。GR 组的复发时间早于 PR 组,复发后两组的肿瘤学结局无差异。